| Not Yet Recruiting | Lacosamide Intravenous Injection for Emergency Termination of Status Epilepticus Epilepsy, Status Epilepticus | — | 2025-06-06 |
| Not Yet Recruiting | Herpes Simplex Virus Type 1 Infection/Reactivation of Patients With Severe Pneumonia（the HSV-SP Study） Severe Pneumonia | — | 2025-06-01 |
| Recruiting | Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus Type 2 Diabetes | Phase 1 / Phase 2 | 2025-06-01 |
| Recruiting | Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC Hepatocellular Carcinoma Non-resectable | Phase 2 | 2025-04-01 |
| Recruiting | Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT Hepatocellular Carcinoma Non-resectable | Phase 2 | 2025-04-01 |
| Recruiting | Y-90 SIRT for Unresectable HCC Larger Than 7cm Hepatocellular Carcinoma Non-Resectable | Phase 2 | 2024-12-01 |
| Recruiting | Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT Hepatocellular Carcinoma Non-resectable | Phase 3 | 2024-08-01 |
| Not Yet Recruiting | Stem Cell Derived Exome for Treatment of Diabetic Foot Diabetic Foot, Stem Cell | Phase 1 / Phase 2 | 2024-08-01 |
| Recruiting | Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma. Hepatic Cancer, Surgery | Phase 2 | 2024-07-01 |
| Recruiting | Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer. Lung Cancer, Surgery, Non-small Cell Lung Cancer | Phase 2 | 2024-07-01 |
| Recruiting | Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT Liver Cancer, Antibody | Phase 2 | 2024-06-10 |
| Recruiting | Anti-cancer DC Cell Vaccination to Treat Solid Tumors Solid Tumor, Adult, DC | Phase 1 | 2024-06-05 |
| Recruiting | Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors Solid Tumor, Adult | Phase 1 | 2024-06-04 |
| Recruiting | GPC3/Mesothelin-CAR-γδT Cells Against Cancers Pancreas Cancer, Lung Cancer, Liver Cancer | Phase 1 | 2024-05-10 |
| Recruiting | Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors Solid Tumor, Adult | Phase 1 | 2024-05-08 |
| Recruiting | DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC Hepatocellular Carcinoma Non-resectable | Phase 2 | 2024-05-01 |
| Recruiting | Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC Hepatocellular Carcinoma Non-resectable | Phase 2 | 2024-05-01 |
| Recruiting | Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT Lung Cancer, Inoperable Disease | Phase 2 | 2024-04-04 |
| Recruiting | Interventional Software for Multi-immunotherapy of Solid Tumors Lung Cancer, Liver Cancer, Solid Tumor, Adult | Phase 2 / Phase 3 | 2024-04-01 |
| Unknown | Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC Thrombocytopenia, Hepatocellular Carcinoma | Phase 2 | 2023-08-14 |
| Recruiting | SIRT for Potentially Resectable HCC Hepatocellular Carcinoma | N/A | 2023-08-10 |
| Recruiting | Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC Hepatocellular Carcinoma | Phase 2 | 2023-08-10 |
| Unknown | Aribulin Combined With Carboplatin and Bevacizumab in the Treatment of Ovarian Cancer Ovarian Cancer | Phase 1 / Phase 2 | 2023-08-01 |
| Unknown | Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma Head and Neck Squamous Cell Carcinoma | Phase 2 | 2023-08-01 |
| Recruiting | Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC Hepatocellular Carcinoma Non-resectable | Phase 3 | 2023-08-01 |
| Unknown | Tirellizumab Combined With Chemotherapy Monotherapy for Non-small Cell Lung Cancer Non-small Cell Lung Cancer | Phase 1 | 2023-08-01 |
| Unknown | Effect of Heart Rate Control With Ivabradine on Hemodynamic in Patients With Sepsis Sepsis, Ivabradine, Hemodynamics | Phase 4 | 2023-06-01 |
| Recruiting | ExtraCorporeal Membrane Oxygenation in the Therapy for REfractory Septic Shock With Cardiac Function Under Est Extracorporeal Membrane Oxygenation, Septic Shock, Septic Cardiomyopathy | N/A | 2023-05-01 |
| Recruiting | Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers Pancreas Cancer, CAR-T Cell Therapy, Mesothelin | Phase 1 | 2023-03-10 |
| Unknown | An Exploratory Clinical Study of Photodynamic Therapy Combined With Sonodynamic Therapy in Cholangiocarcinoma Cholangiocarcinoma | N/A | 2022-12-01 |
| Recruiting | Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC Hepatocellular Carcinoma Non-resectable | Phase 3 | 2022-11-02 |
| Recruiting | Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC Hepatocellular Carcinoma Non-resectable | Phase 3 | 2022-11-02 |
| Unknown | Clinical Analysis of Simultaneous Pancreas-kidney Transplantation for End-stage Renal Disease Associated With Diabetes Mellitus；Uremia | N/A | 2022-09-01 |
| Completed | SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCC Hepatocellular Carcinoma Non-resectable | — | 2022-06-01 |
| Recruiting | CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors Stage IV Ovarian Cancer, Testis Cancer, Refractory, Endometrial Cancer Recurrent | Phase 1 | 2022-06-01 |
| Recruiting | EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer EGFR/ B7H3-positive Advanced Lung Cancer, EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer | EARLY_Phase 1 | 2022-05-01 |
| Unknown | DEB-TACE+HAIC vs. HAIC for Large HCC Unresectable Hepatocellular Carcinoma | Phase 3 | 2022-02-10 |
| Completed | Donafenib Plus Sintilimab for Advanced HCC Hepatocellular Carcinoma | Phase 2 | 2021-12-04 |
| Recruiting | Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors Lung Cancer, Liver Cancer, Colorectal Cancer | Phase 1 / Phase 2 | 2021-11-01 |
| Unknown | TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT Hepatocellular Carcinoma Non-resectable | N/A | 2021-07-09 |
| Unknown | DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC Hepatocellular Carcinoma Non-resectable | N/A | 2021-07-09 |
| Recruiting | Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Lung Cancer, Hepatocellular Carcinoma, Solid Tumor | Phase 1 | 2021-03-01 |
| Unknown | Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC Hepatocellular Carcinoma Non-resectable | Phase 2 | 2021-01-09 |
| Completed | Enhanced Recovery After Surgery for SPK Transplantation Recipients Transplant Complication, Diabetic Nephropathy, Perioperative/Postoperative Complications | N/A | 2021-01-01 |
| Recruiting | Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors Liver Cancer, Lung Cancer, Breast Cancer | Phase 1 | 2021-01-01 |
| Recruiting | Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors Solid Tumor, Adult, Hepatocellular Carcinoma | Phase 2 | 2021-01-01 |
| Completed | The Feasibility of Sugammadex for General Anesthesia in Patients Undergoing Kidney and Pancreas Transplantatio Surgery | N/A | 2020-12-18 |
| Recruiting | Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs Hepatocellular Carcinoma, Solid Tumor, Adult | Phase 2 | 2020-11-01 |
| Completed | TACE Combined With Sorafenib and Tislelizumab for Advanced HCC Hepatocellular Carcinoma Non-resectable | Phase 2 | 2020-10-01 |
| Completed | TACE Combined With Lenvatinib and Sintilimab for Advanced HCC Hepatocellular Carcinoma Non-resectable | Phase 2 | 2020-10-01 |
| Unknown | TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC Hepatocellular Carcinoma Non-resectable | Phase 1 | 2020-09-27 |
| Completed | Preadmission Metformin Exposure and Incidence of Acute Kidney Injury AKI | — | 2020-08-01 |
| Recruiting | Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC Non Small Cell Lung Cancer | EARLY_Phase 1 | 2019-09-01 |
| Unknown | CRRT Timing in Sepsis-associated AKI in ICU Sepsis-Associated Organ Dysfunction, RTT | N/A | 2019-08-22 |
| Completed | Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT Hepatocellular Carcinoma Non-resectable | — | 2019-07-01 |
| Recruiting | Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I Anti-cancer Cell Immunotherapy, T Cell and NK Cell | Phase 1 / Phase 2 | 2019-01-01 |
| Recruiting | Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma Liver Cancer | Phase 3 | 2019-01-01 |
| Recruiting | IT or IA Infusion of PD1/PDL1/CTLA4 Inhibitors Versus IV for Immunotherapy of Head/Neck Cancers (HNC) Head/Neck Neoplasm | Phase 2 / Phase 3 | 2019-01-01 |
| Recruiting | TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors Nonsmall Cell Lung Cancer, Solid Tumor, Adult | Phase 1 | 2018-12-01 |
| Recruiting | Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC Non Small Cell Lung Cancer | N/A | 2018-11-01 |
| Recruiting | Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Hepatocarcinoma, Lung Cancer, Melanoma | Phase 2 / Phase 3 | 2018-11-01 |
| Unknown | TACE Combined With Iodine-125 Seeds Implantation for HCC Hepatocellular Carcinoma, Portal Vein Occlusion, Tumor Thrombus | N/A | 2018-07-01 |
| Unknown | Restricted Calorie Ketogenic Diet as a Treatment in Malignant Tumors Malignant Tumors | N/A | 2018-03-01 |
| Unknown | Pregabalin Treatment and Prevention Post-herpetic Neuralgia Herpetic Neuralgia | Phase 3 | 2017-10-01 |
| Unknown | HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions Epilepsy, Neuropathy, Psychiatric Illness | N/A | 2017-08-01 |
| Recruiting | GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers Lung Cancer, Cancer, Immunotherapy | Phase 1 | 2017-07-01 |
| Recruiting | GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression Hepatocellular Carcinoma, Immunotherapy, CAR | Phase 1 | 2017-07-01 |
| Recruiting | iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray Lung Cancer, Gene Abnormality, Gene Product Sequence Variation | — | 2017-07-01 |
| Unknown | A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Lymphoma | Phase 1 / Phase 2 | 2017-06-30 |
| Unknown | Efficacy and Safety of Weight-Based Insulin Titration Regimen in Hospitalized Patients With Type 2 Diabetes Efficacy, Self, Adverse Effect | N/A | 2017-06-01 |
| Unknown | Islet Allotransplantation for Type 1 Diabetic Patients Type 1 Diabetic | Phase 3 | 2017-04-23 |